DelveInsight’s, “H1N1 Infection Pipeline Insights 2026” Report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in H1N1 Infection pipeline landscape. It covers the H1N1 Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the H1N1 Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the H1N1 Infection Pipeline @ H1N1 Infection Pipeline Outlook

Key Takeaways from the H1N1 Infection Pipeline Report

• On April 07, 2026- French National Agency for Research on AIDS and Viral Hepatitis initiated a phase II trial is to evaluate the immunogenicity and safety of a A(H1N1)French National Agency for Research on AIDS and Viral Hepatitis influenza vaccine, administered with or without adjuvant, in HIV-infected patients after one or two injections.
• In March 2026- Seqirus conducted a Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age. The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.
• DelveInsight’s H1N1 Infection pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for H1N1 Infection treatment.
• The leading H1N1 Infection Companies such as SAB Biotherapeutics, Codagenix, Inc, Cocrystal Pharma, Collaborations Pharmaceuticals, Vaxart, Inc., Adimmune Corporation, Model Medicines, NanoViricides, Ansun Biopharma, Immune Therapeutics, Inc., Ena Respiratory, EpiVax, Inc., Mayly Life Sciences, Recce Pharmaceuticals, Vivaldi Biosciences, Sonnet BioTherapeutics and others.
• Promising H1N1 Infection Pipeline Therapies such as Arepanrix, SAB-176, MF59-eH1N1_f, CSL425, VXA-A1.1, Fluzone®, Focetria®, Begrivac® and others.

Stay ahead with the most recent pipeline outlook for H1N1 Infection @ H1N1 Infection Treatment Drugs

The H1N1 Infection Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The H1N1 Infection Pipeline Report also highlights the unmet needs with respect to the H1N1 Infection.

H1N1 Infection Overview

H1N1 influenza, commonly referred to as swine flu, is an infectious disease caused by the H1N1 strain of the influenza A virus. This virus is notable for its rapid transmission and ability to cause significant respiratory illness in humans. The H1N1 strain gained global prominence during the 2009 pandemic, which originated in Mexico and quickly spread worldwide. This particular strain is a reassortant virus, meaning it contains genetic material from human, swine, and avian influenza viruses, contributing to its unique properties and impact. The transmission of H1N1 occurs primarily through respiratory droplets when an infected person coughs or sneezes. It can also spread by touching surfaces contaminated with the virus and then touching the nose or mouth. Symptoms of H1N1 infection are similar to those of seasonal flu and include fever, cough, sore throat, body aches, headache, chills, and fatigue. In some cases, individuals may also experience vomiting and diarrhea. While most cases are mild, H1N1 can lead to severe illness, particularly in young children, elderly individuals, pregnant women, and those with underlying health conditions.

H1N1 Infection Emerging Drugs Profile

• SAB 176: SAB Biotherapeutics

SAB-176 is a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate in development for the treatment or prevention of severe influenza. The novel, specifically-targeted therapeutic leverages the natural human biological immune response to specifically bind to Type A and Type B influenza viruses. Like vaccines, it can be modified to address annual strain changes, when needed, to maintain broader coverage as the flu virus mutates. Preclinical data suggests that SAB-176 offers broad protection against diverse influenza strains. The drug is currently in Phase II stage of clinical trial evaluation to treat Influenza A H1N1.

• CodaVax™-H1N1: Codagenix

A live-attenuated influenza vaccine, CodaVax-H1N1, is being developed by Codagenix. The vaccine enables presentation of conserved antigens of the wild-type virus, demonstrating universal potential in primate models and thus the potential to provide multi-season protection when developed into its final quadrivalent formulation. Currently, it is in Phase I stage of clinical trial evaluation to treat H1N1 infection.

The H1N1 Infection Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of H1N1 Infection with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for H1N1 Infection Treatment.
• H1N1 Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• H1N1 Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the H1N1 Infection market

Explore groundbreaking therapies and clinical trials in the H1N1 Infection Pipeline @ New H1N1 Infection Drugs

H1N1 Infection Companies

SAB Biotherapeutics, Codagenix, Inc, Cocrystal Pharma, Collaborations Pharmaceuticals, Vaxart, Inc., Adimmune Corporation, Model Medicines, NanoViricides, Ansun Biopharma, Immune Therapeutics, Inc., Ena Respiratory, EpiVax, Inc., Mayly Life Sciences, Recce Pharmaceuticals, Vivaldi Biosciences, Sonnet BioTherapeutics and others.

H1N1 Infection Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

H1N1 Infection Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn about new drugs, pipeline developments with DelveInsight’s expert analysis @ H1N1 Infection Market Drivers and Barriers

Scope of the H1N1 Infection Pipeline Report

• Coverage- Global
• H1N1 Infection Companies- SAB Biotherapeutics, Codagenix, Inc, Cocrystal Pharma, Collaborations Pharmaceuticals, Vaxart, Inc., Adimmune Corporation, Model Medicines, NanoViricides, Ansun Biopharma, Immune Therapeutics, Inc., Ena Respiratory, EpiVax, Inc., Mayly Life Sciences, Recce Pharmaceuticals, Vivaldi Biosciences, Sonnet BioTherapeutics and others.
• H1N1 Infection Pipeline Therapies such as Arepanrix, SAB-176, MF59-eH1N1_f, CSL425, VXA-A1.1, Fluzone®, Focetria®, Begrivac® and others.
• H1N1 Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• H1N1 Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on H1N1 Infection Therapies and clinical trials @ H1N1 Infection Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. H1N1 Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. H1N1 Infection– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SAB 176: SAB Biotherapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CodaVax™-H1N1: Codagenix
15. Drug name : Company name
16. Drug profiles in the detailed report…..
17. Preclinical and Discovery Stage Products
18. Drug name : Company name
19. Drug profiles in the detailed report…..
20. Inactive Products
21. H1N1 Infection Key Companies
22. H1N1 Infection Key Products
23. H1N1 Infection- Unmet Needs
24. H1N1 Infection- Market Drivers and Barriers
25. H1N1 Infection- Future Perspectives and Conclusion
26. H1N1 Infection Analyst Views
27. H1N1 Infection Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/h1n1-infection-pipeline-insight